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Abstract
Background:  HIV and TB infections are both associated with elevated oxidative stress parameters. Anti-oxidant supplemen-
tation may offer beneficial effects in positively modulating oxidative stress parameters in HIV and HIV-TB infected patients. 
We investigated the effects of  vitamin A and C supplementation on oxidative stress in HIV infected and HIV-TB co-infected 
subjects.
Methods: 40 HIV/TB co-infected and 50 HIV mono-infected patients were divided into 2 equal groups. Participants provided 
demographic information and blood was collected to determine oxidative stress parameters before and after vitamin A (5000 
IU) and C (2600 mg) supplementation for 1 month.
Results: There was a significantly (p < 0.05) higher level of  Malondialdehyde (MDA) at baseline for HIV infected subjects com-
pared with HIV-TB co-infected subjects. There was a significantly (p < 0.05) lower level of  MDA and higher level of  Catalase 
(CAT) in subjects administered supplementation compared to subjects without supplementation for the HIV infected group. 
There was a significantly lower level of  Reduced Glutathione (GSH), Superoxide Dismutase (SOD) and higher level of  MDA 
after one month of  supplementation compared with baseline levels for HIV/TB co infected subjects. A similar result was also 
obtained for the HIV mono-infected groups which had a significantly lower level of  SOD, MDA and CAT compared to the 
baseline. There was a significantly lower level of  GSH and SOD, and higher level of  MDA after supplementation compared with 
the baseline for HIV/TB co-infected subjects.
Comparing the indices at baseline and post no-supplementation in HIV/TB co-infection showed no significant differences in 
the oxidative stress parameters
Conclusion: HIV/TB co-infection and HIV mono-infection seems to diminish the capacity of  the anti-oxidant system to con-
trol oxidative stress, however exogenous anti-oxidant supplementation appears not to have beneficial roles in positively modu-
lating the associated oxidative stress.
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Acquired Immune Deficiency Syndrome is a fatal illness 
caused by a retrovirus known as the human immunodefi-
ciency virus (HIV) that breaks down the body’s immune 
system, infects CD4+ cells initially, progressively and 
ultimately leads to a chronic depletion of  the immune 
system.1,2   This syndrome is often associated with rare 
opportunistic infections which includes Mycobacterium tu-
berculosis, pneumonia and others.3 Among the opportunis-
tic pathogens associated with AIDS, Mycobacterium tubercu-
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losis possesses a large number of  virulence factors and has 
a higher potential  for person-to-person transmission.4
Persons infected with HIV are particularly susceptible to 
tuberculosis, both from the reactivation of  latent infec-
tion and from new infection with rapid progression to 
active disease.5,6 In 2008, more than one-third of  HIV-in-
fected individuals were also infected with tuberculosis 
(TB).7 Studies from 2007 show that of  the 9.3 million 
new TB cases, 1.4 million were also living with HIV and 
500,000 HIV positive TB patients died that same year. In 
many parts of  the world TB is a leading cause of  death in 
individuals infected with HIV.7,8
It is believed that oxidative stress played a major role in 
the progression of  HIV infection.8,9,10  Oxidative stress 
is also associated with the pathophysiology of  other dis-
ease like diabetes, and Alzheimer’s disease.11,12 Substantial 
amount of  evidence revealed roles of  Oxidative Stress 
(OS) as a contributory factor in many infections and drug 
related toxicities.13
Experiments in animals have established the involvement 
of  oxidative stress in drug induced toxic reaction.14 A dys-
function of  anti-oxidant system have also been observed 
in patients on anti-retroviral therapy, suggesting the roles 
of  oxidative stress in antiretroviral toxicities, this is be-
cause Highly Active Antiretroviral Therapy (HAART) 
seems to elevate reactive oxidative species in circulation, 
by producing more oxidized species due to the reactions 
between ROS and cellular molecular components.15,16 
HIV alone or and in combination with anti-retroviral 
therapies contributes to the development of  oxidative 
stress in humans.
Oxidative stress also has been shown to be associated 
with TB infection through activation of  phagocytes by 
mycobacteria which may further contribute to immuno-
suppression.17,18 High level of  oxidative stress has been 
reported in patients with tuberculosis as a result of  tissue 
inflammation, poor nutrition and poor immunity and this 
stress becomes more severe in those with HIV-TB co-in-
fection. Furthermore, a report has shown high levels of  
oxidative stress in HIV-TB co-infected patients.19
Patients infected with HIV are in oxidative imbalance 
early in the disease; serum and tissue anti-oxidants levels 
are low and peroxidation products elevated.20 High plas-
ma levels of  malondialdehyde (MDA), reduced plasma 
glutathione (GSH), and decreased superoxide dismutase 
(SOD) activities are normally found. HIV and TB infec-
tion also result in considerably reduced vitamin C con-
centrations.21
Anti-oxidant supplementation may help protect against 
oxidative stress associated with the infection and drug 
therapy. This study was therefore conducted to identify 
the modulatory roles of  vitamin A and C supplementa-
tion on oxidative stress associated with HIV mono-infec-
tion and HIV-TB co-infection
Methods
Study site
The study was conducted at the AIDS Prevention Initia-
tive of  Nigeria (APIN) Clinic, Lagos University Teaching 
Hospital, Lagos, Nigeria; which is one of  the treatment 
centers and a research center for the HIV relief  program 
in Nigeria. The clinic runs from 8:00 a.m. to 4:00 p.m. 
(Monday to Friday) and has over 10,000 registered pa-
tients with an average of  200 patients attended to per day.
Subjects
A total of  90 consenting patients consisting of  male and 
female adults with HIV infection (17 males, 33 females) 
and HIV-TB co-infection (10 males, 30 females) attending 
the AIDS Prevention Initiative of  Nigeria (APIN) Clinic 
of  the Lagos University  Teaching Hospital (LUTH).
This was a prospective randomized study to determine 
the effect of  vitamin A 5000 IU and vitamin C 2600 mg 
on oxidative stress markers in HIV infected and HIV-TB 
co-infected patients.
Ethical approval and patients’ consent
Ethical approval was obtained from the Research and 
Ethics Committee of  Lagos University Teaching Hospi-
tal, (LUTH), Lagos, Nigeria.
Inclusion criteria
Subjects with HIV infection and HIV-TB co-infection ≥ 
18 years of  age who gave informed consent were used.
Exclusion criteria
Patients with:
-  Co-morbidities, such as renal, endocrine, hepatic dis-
eases were excluded from the study so that they would 
not act as confounders to the study.
-   Pregnant or lactating women were also excluded from 
the study.
-  CD4 count > 350 cells/micro-liter were also excluded 
from the study.
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Sample population and study procedure
Fifty (50) HIV infected and forty (40) HIV-TB co-infect-
ed subjects who met the inclusion criteria were recruited 
from 15th May 2013 to 30th January 2014. Information 
collected after obtaining consent includes bio-data, CD4+ 
count, viral load, hematological parameters and clinical 
chemistry parameters.
HIV treatment naive subjects (50 subjects) were recruited 
as they presented to the clinic and 5mls of  blood samples 
in heparinized vacutainer was collected for baseline ox-
idative stress parameters. Blood samples were collected 
at subjects’ first clinic visit for estimation of  full blood 
count, chemistry, CD4+ count and viral load 2 weeks pri-
or to when samples for estimation of  baseline oxidative 
stress parameters were collected.
The 50 HIV infected subjects were systematically ran-
domized into 2 groups as follows:
I.   25 HIV infected subjects on supplementation (group 
A)
II. 25 HIV infected subjects without supplementation 
(group B)
5mls of  blood was collected from both groups; pre-sup-
plementation and at 1month post-supplementation with 
vitamin A and vitamin C.
The 40 HIV-TB co-infected subjects were systematically 
randomized into:
I.  20 HIV-TB co-infected subjects on supplementation 
(group C)
II. 20 HIV-TB infected subjects without supplementation 
(group D)
5mls of  blood was collected from both groups; pre-sup-
plementation and at 1month post-supplementation with 
vitamin A and vitamin C.
Modalities of  providing supplementation
Group A and C were given supplements (Vitamin A 5000 
IU and Vitamin C 2600 mg) contained in EMVITE multi-
vitamin tablets. EMVITE multi-vitamin tablets produced 
by EMZOR Pharmaceutical Industries Ltd, with batch 
number 3 19698 and 04, 2013 as date of  manufacture 
and 04, 2016 as expiry date were used. Each tablet con-
tained vitamin A acetate 2500 IU, vitamin B1 600 mcg, 
vitamin D 250 IU, vitamin C 13000 mcg. It was ensured 
that subjects adhered to the required number of  tablets 
to be taken daily.
These doses can be tolerated in humans according to 
Pappolla et al, Schipper et al and Ayinde et al , hence were 
chosen for the study.22, 23,24
Sample and statistical analysis
Plasma samples were separated from whole blood by cen-
trifuging in a Whisperfuge centrifuge Model 684 (GEA 
Westfalia, Northvale, NJ, USA) at 2500 rpm for 10 min-
utes and was stored in Nuaire - 80oC ultralow tempera-
ture freezer, model number NU-9668E, serial number 
08040061, until ready for analysis.
CD4+ count, clinical chemistry and hematological param-
eters were determined using Automated Cy-flow count-
er; Hitachi 90 and Mindray BC 3200 respectively. Viral 
load was determined using Automated Ampliprep Cobas 
Taqman 48 analyzer.
Antioxidant enzymes assay
Measurements of  anti-oxidant enzyme activity and lip-
id peroxidation were performed according to standard 
procedures. Catalase, superoxide dismutase (SOD), 25 
malondialdehyde (MDA),26 reduced glutathione (GSH) 




Age range of  the recruited HIV subjects
The results showed that the recruited HIV infected pa-
tients were in the age range 23 years to 58 years. Most 
were in the productive age group.
Sex distribution of  recruited HIV subjects
The sex distribution of  the subjects showed that the fe-
male: male ratio was in proportion of  2:1. A total of  17 
male and 33 female HIV infected subjects who gave in-
formed consent were recruited. (Fig. 1)
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Fig 1: Sex distribution of  recruited HIV subjects.
Age range of  the recruited HIV-TB co-infected 
study subjects
The results showed that the recruited HIV-TB infected 
patients were in the age range 28 years to 58 years. Most 
were in their productive age group.
Sex distribution of  the recruited HIV-TB co-infect-
ed study subjects
The sex distribution of  the subjects showed that the fe-
male: male ratio was in proportion of  3:1. A total of  10 
males and 30 females HIV-TB co-infected subjects who 
gave informed consent were recruited. (Fig. 2)
Fig 2: Sex distribution of  the recruited HIV-TB co-infected study subjects
Baseline CD+ count and viral load in HIV infected 
subjects
The mean baseline CD4+ count and viral load were 
164.61 cells/μL and 540,284.44 copies/mL. The low 
CD4+ count and viral load showed both immune-depres-
sion and immuno-suppression.
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Baseline clinical chemistry parameters in HIV-in-
fected subjects
The mean baseline clinical chemistry parameters in the 
recruited HIV infected subjects showed that levels of  
urea and creatinine were 12.27 mol/L and 48.98 µmol/L 
respectively. These suggest that there was renal impair-
ment. The mean values of  hepatic enzymatic biomarkers; 
AST, ALT, ALP was also increased suggesting evidence 
of  liver injury.
Oxidative stress parameters in HIV infected subjects 
one month post-supplementation
There was significant (p < 0.05) differences in CAT and 
MDA levels in HIV subjects one month post-supplemen-
tation. (Table 1)
Table 1: Oxidative stress parameters in HIV infected subjects 





Vitamin A & 





Mean ± SEM Mean ± SEM 
GSH 0.67  ±  0.54 0.56 ± 0.55 0.603 
SOD 1.97 ± 1.16 2.29 ± 0.89 0.307 
CAT 14.21 ± 4.90 17.42 ± 3.41 0.026* 
MDA 0.03 ± 0.02 0.02 ± 0.01 0.008* 
    
   GSH, Reduced Glutathione; SOD, Superoxide Dismutase; CAT, Catalase; MDA, Malondialdehyde. 
   Result are expressed as mean±SEM * p < 0.05 Supplementation vs No supplementation 
Discussion
Oxidative stress is thought to play an important role in 
the progression of  HIV infection. There is clear evidence 
that oxidative stress contributes to several aspects of  
HIV disease, including viral replication, inflammatory re-
sponse and decreased immune cell proliferation.28 There 
is a profound interplay of  oxidative stress in tuberculosis. 
In pulmonary tuberculosis, there is increase in several cir-
culating markers of  free radical activity, indicating ongo-
ing oxidative stress and decrease in anti-oxidant activity 
which may contribute to development of  lung function 
abnormalities.29 This study was conducted to investigate 
the modulatory effects of  exogenous anti-oxidant sup-
plementation on disease progression in HIV mono – in-
fected and HIV-TB co-infected subjects.
Ninety subjects were recruited for this study; fifty HIV 
infected, and forty HIV/TB co-infected. Sex distribution 
of  the recruited subjects showed that the ratio of  male to 
female for the HIV mono-infected subjects was 2:1 while 
HIV/TB co-infected subjects had a ratio of  3:1. There-
fore recruited subjects had similar sex distribution with a 
higher proportion of  females in both groups.
The hematological parameters at baseline in the HIV in-
fected group showed lower hemoglobin and red blood 
cell count compared with the general reference value 
hence suggesting anemia. A major feature in HIV pa-
tients is the presence of  low level of  hemoglobin and red 
blood cell.30,31 Apart from HIV induced anemia, zidovu-
dine is also associated with anemia especially in women.31
The level of  clinical chemistry parameters in HIV infect-
ed subjects at baseline shows elevated mean total pro-
tein, AST and ALT levels and a lower level of  creatinine 
compared to the normal reference range. This shows a 
possibility of  hepatotoxicity that is characterized by an 
elevation of  hepatic enzymatic biomarkers. One of  the 
adverse effects of  anti-retroviral therapy is hepatotoxicity 
and is frequently reported in patients taking nevirapine 
containing highly active antiretroviral therapy. Case re-
ports, clinical trials and other studies have linked nevirap-
ine with hepatotoxicity in HIV patients taking nevirapine 
containing ART.32
In this study, there was a significantly higher level of  
CAT in HIV mono-infected subjects who had no sup-
plementation when compared with subjects administered 
vitamin A and vitamin C.  Also, the oxidative stress indi-
ces were significantly lower in the post-supplementation 
group compared to baseline. HIV infected subjects have 
been shown to have decreased anti-oxidant concentra-
tions, disruption in glutathione metabolism and enhanced 
spontaneous generation of  reactive oxygen species.33 Fri-
Table 1: Oxidative stress parameters in HIV infected subjects 
one month post-supplementation 
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is-Moller et al.20 have shown that HIV-infected patients 
are in oxidative imbalance early in the disease; serum and 
tissue anti-oxidants levels are low and lipid peroxidation 
products elevated. These supplements were unable to cor-
rect this oxidative state or induce an increase/stimulation 
of  the anti-oxidant system. The first stage of  metabolism 
of  vitamin C converts it into a free radical34 which could 
exacerbate oxidative stress in conditions characterized by 
excessive oxidation. This is further corroborated by the 
significantly lower levels of  MDA in subjects who had no 
supplementation when compared with the subjects who 
had supplementation. According to Mehta and Fawzi,35 
advanced HIV disease may suppress release of  vitamin 
A from the liver and would result in low levels of  vita-
min A in the plasma despite the body having enough vita-
min A liver stores. These authors35 also reported that the 
HIV genome has a retinoic acid receptor element hence 
vitamin A may increase HIV replication via interacting 
with this receptor. Vitamin A is also known to increase 
lymphoid cell differentiation, which leads to an increase 
in CCR5 receptors which are essential for attachment of  
HIV to the lymphocytes and therefore, an increase in 
their number is likely to increase HIV replication. This 
may be a probable mechanism for the non-efficacious ef-
fect of  this vitamin seen in this study.
In HIV-TB co infected subjects in this study, there were 
significantly higher levels of  GSH and SOD in subjects 
who had no supplementation compared with the Vitamin 
A and C administered subjects. Comparing post-supple-
mentation levels of  oxidative stress indices with baseline 
showed significantly lower levels of  SOD and CAT with 
a corresponding significantly higher level of  MDA at 
post-supplementation. Loss of  appetite, poor intestinal 
absorption, increased urinary loss of  vitamin A or acute 
phase reaction in tuberculosis36 may contribute to these 
findings and portends that these supplements were un-
able to confer protective roles as anti-oxidants against 
oxidative stress at the experimental doses used and may 
provide no benefit also in HIV-TB coinfection.
A higher level of  MDA in these subjects points to in-
creased lipid peroxidation further indicating the inability 
of  vitamin C and A to shield the patients from medi-
cation or infection induced oxidation and hence disease 
progression.
Conclusion
This study shows that there are no positive modulatory 
roles and benefits of  vitamin C and A supplementation 
on oxidative stress indices in HIV mono-infected and 
HIV-TB co-infected patients.
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